Healthcare provider profile · identity verified

Kevin Hou, MD

Internal Medicine · LONE TREE, CO · NPI 1447644372

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	495	209
Rosuvastatin Calcium	Rosuvastatin Calcium	434	194
Levothyroxine Sodium	Levothyroxine Sodium	339	139
Amlodipine Besylate	Amlodipine Besylate	318	132
Losartan Potassium	Losartan Potassium	279	123
Omeprazole	Omeprazole	186	72
Lisinopril	Lisinopril	173	83
Tamsulosin Hcl	Tamsulosin Hcl	147	58
Metoprolol Succinate	Metoprolol Succinate	141	57
Metformin Hcl	Metformin Hcl	122	50
Hydrochlorothiazide	Hydrochlorothiazide	118	50
Simvastatin	Simvastatin	111	40
Trazodone Hcl	Trazodone Hcl	109	47
Ezetimibe	Ezetimibe	101	44
Pantoprazole Sodium	Pantoprazole Sodium	98	43
Allopurinol	Allopurinol	97	45
Eliquis	Apixaban	90	30
Gabapentin	Gabapentin	87	43
Olmesartan Medoxomil	Olmesartan Medoxomil	83	37
Finasteride	Finasteride	81	28
Clopidogrel	Clopidogrel Bisulfate	76	34
Furosemide	Furosemide	74	30
Montelukast Sodium	Montelukast Sodium	70	32
Ipratropium Bromide	Ipratropium Bromide	66	49
Escitalopram Oxalate	Escitalopram Oxalate	61	29
Metformin Hcl Er	Metformin Hcl	61	29
Pravastatin Sodium	Pravastatin Sodium	61	28
Sertraline Hcl	Sertraline Hcl	60	26
Atenolol	Atenolol	56	23
Zolpidem Tartrate	Zolpidem Tartrate	55	24
Potassium Chloride	Potassium Chloride	48	15
Synthroid	Levothyroxine Sodium	46	18
Famotidine	Famotidine	44	25
Metoprolol Tartrate	Metoprolol Tartrate	43	19
Spironolactone	Spironolactone	41	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	40	16
Duloxetine Hcl	Duloxetine Hcl	39	15
Citalopram Hbr	Citalopram Hydrobromide	37	15
Carvedilol	Carvedilol	34	17
Meloxicam	Meloxicam	34	21
Fluoxetine Hcl	Fluoxetine Hcl	32	13
Fluticasone Propionate	Fluticasone Propionate	32	17
Mounjaro	Tirzepatide	32	suppressed
Valsartan	Valsartan	32	14
Xarelto	Rivaroxaban	32	15
Albuterol Sulfate Hfa	Albuterol Sulfate	31	19
Ozempic	Semaglutide	29	suppressed
Valacyclovir	Valacyclovir Hcl	28	20
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	26	25
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	26	15
Diclofenac Sodium	Diclofenac Sodium	25	suppressed
Estradiol	Estradiol	24	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	23	suppressed
Alprazolam	Alprazolam	21	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Celecoxib	Celecoxib	20	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Hydralazine Hcl	Hydralazine Hcl	19	suppressed
Naproxen	Naproxen	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Glimepiride	Glimepiride	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	13	suppressed
Donepezil Hcl	Donepezil Hcl	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	13
Methylprednisolone	Methylprednisolone	13	13
Mirtazapine	Mirtazapine	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Ramipril	Ramipril	13	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Azithromycin	Azithromycin	11	11
Clonidine Hcl	Clonidine Hcl	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error